We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Response to Pegylated Interferon Plus Ribavirin Among HIV/Hepatitis C Virus–Coinfected Patients With Compensated Liver Cirrhosis.
- Authors
Mira, José A.; García-Rey, Silvia; Rivero, Antonio; de los Santos-Gil, Ignacio; López-Cortés, Luis F.; Girón-González, José A.; Téllez, Francisco; Márquez, Manuel; Merino, Dolores; Ríos-Villegas, María J.; Macías, Juan; Rivero-Juárez, Antonio; Pineda, Juan A.
- Abstract
The efficacy of pegylated interferon plus ribavirin in human immunodeficiency virus/hepatitis C virus (HCV)–coinfected patients with compensated cirrhosis is lower than in those without cirrhosis, although this antiviral combination still leads to a substantial rate of sustained virologic response in those carrying HCV genotype 3.Background. The objective of this study was to determine the efficacy of pegylated interferon (peg-IFN) plus ribavirin (RBV) in human immunodeficiency virus (HIV)–infected patients with hepatitis C virus (HCV)–related compensated liver cirrhosis, as well as the predictors of response in these individuals.Methods. All subjects enrolled in a prospective cohort of 841 HIV/HCV-coinfected patients who received peg-IFN and RBV and who had a liver biopsy or a liver stiffness measurement within the year before starting peg-IFN plus RBV were included in this study. The sustained virologic response (SVR) rate and predictors of SVR response were analyzed.Results. A total of 629 patients were included in this study; 175 (28%) had cirrhosis. In an intention-to-treat analysis, 44 (25%) patients with cirrhosis and 177 (39%) without cirrhosis achieved SVR (P = .001). Among patients with cirrhosis, SVR was observed in 14%, 47%, and 30% of individuals with HCV genotypes 1, 2–3, and 4, respectively. Discontinuation of therapy owing to adverse events was observed in 30 (17%) individuals with cirrhosis and 37 (8%) subjects without cirrhosis (P = .001).Conclusions. The efficacy of peg-IFN plus RBV among HIV/HCV-coinfected patients with cirrhosis is lower than in those without cirrhosis, although this antiviral combination still leads to a substantial rate of SVR in those carrying HCV genotype 3. A higher rate of discontinuations of HCV therapy due to adverse events among cirrhotic patients could partially explain the differences in the SVR rate between both populations.
- Subjects
INTERFERONS; RIBAVIRIN; CIRRHOSIS of the liver; HEPATITIS C; HIV infections; DRUG efficacy; ANTIVIRAL agents
- Publication
Clinical Infectious Diseases, 2012, Vol 55, Issue 12, p1719
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/cis779